Semustine | CAS#13909-09-6 | Lomustine Derivative

MedKoo Cat#: 100765 | Name: Semustine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Semustine is a drug used in chemotherapy. It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.

Chemical Structure

Semustine

CAS#13909-09-6

Theoretical Analysis

MedKoo Cat#: 100765

Name: Semustine

CAS#: 13909-09-6

Chemical Formula: C10H18ClN3O2

Exact Mass: 247.1088

Molecular Weight: 247.72

Elemental Analysis: C, 48.48; H, 7.32; Cl, 14.31; N, 16.96; O, 12.92

Price and Availability

Size	Price	Availability
1mg	USD 150.00	Ready to ship
5mg	USD 450.00	Ready to ship
10mg	USD 750.00	Ready to ship
25mg	USD 1,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CCNU methyl, MCCNU, methyl CCNU, methylCCNU, MeCCNU

IUPAC/Chemical Name

N-(2-Chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea

InChi Key

FVLVBPDQNARYJU-UHFFFAOYSA-N

InChi Code

InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15)

SMILES Code

O=C(NC1CCC(C)CC1)N(CCCl)N=O

Appearance

White to light yellow crystalline power

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

semustine is a methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Certificate of Analysis

View CoA: current batch, Lot#S7C12B06

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Semustine serves as a DNA alkylator.

In vitro activity:

Reduced mitotic activity and prolonged average generation time was observed in MeCCNU treated cultures. The results suggest that 'therapeutic' MeCCNU concentrations have genotoxic effects on human peripheral blood lymphocytes. Reference: Vyas RC, Adhvaryu SG, Shah VC. Genotoxic effects of MeCCNU on human peripheral blood lymphocytes. Toxicol Lett. 1988 Nov;44(1-2):153-9. doi: 10.1016/0378-4274(88)90141-5. PMID: 3188073.

In vivo activity:

The development of resistance to MeCCNU in four clonal lines of Lewis lung carcinoma derived from lung colonies has been examined. Treatment of the clones with 15 mg/kg MeCCNU once in each in vivo passage resulted in a rapid reduction in tumour responsiveness to this drug. Reference: McMillan TJ, Stephens TC, Peacock JH, Steel GG. Development of MeCCNU-resistance in clonally derived lines of Lewis lung carcinoma. Eur J Cancer Clin Oncol. 1987 Jun;23(6):801-5. doi: 10.1016/0277-5379(87)90282-3. PMID: 3653197.

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	403.68
	H2O	50.0	201.84

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 247.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1: Vyas RC, Adhvaryu SG, Shah VC. Genotoxic effects of MeCCNU on human peripheral blood lymphocytes. Toxicol Lett. 1988 Nov;44(1-2):153-9. doi: 10.1016/0378-4274(88)90141-5. PMID: 3188073. 2: Harrison SD Jr, Mann DM, Giles RC Jr. Effect of nitrosoureas on calmodulin activity in vitro and in mouse intestine in vivo. Cancer Chemother Pharmacol. 1985;14(2):146-9. doi: 10.1007/BF00434354. PMID: 2982510.

In vivo protocol:

1: McMillan TJ, Stephens TC, Peacock JH, Steel GG. Development of MeCCNU-resistance in clonally derived lines of Lewis lung carcinoma. Eur J Cancer Clin Oncol. 1987 Jun;23(6):801-5. doi: 10.1016/0277-5379(87)90282-3. PMID: 3653197. 2: Song Y, Lu M, Feng L, Chen Q, Huang H, Lin Q. Identification of potential immunotherapy biomarkers for breast cancer by bioinformatics analysis. Biosci Rep. 2022 Feb 25;42(2):BSR20212035. doi: 10.1042/BSR20212035. PMID: 35037689; PMCID: PMC8819662.

1: Kobiakov GL. [Clinical significance of mustoforan in management of malignant glioma]. Vopr Onkol. 2007;53(6):724-9. Review. Russian. PubMed PMID: 18416147. 2: Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed PMID: 11219485. 3: Kodaira S, Shatari T, Nozawa K. [Recent advances is surgical adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho. 2000 Dec;27(14):2201-8. Review. Japanese. PubMed PMID: 11142163. 4: Saka M, Sasako M, Katai H, Sano T. [Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2033-42. Review. Japanese. PubMed PMID: 11103234. 5: Hay JM, Msika S. [Radiotherapy and chemotherapy in the treatment of cancer of the rectum]. J Chir (Paris). 2000 Feb;137(1):13-5. Review. French. PubMed PMID: 10790613. 6: Tsukagoshi S. [Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies]. Gan To Kagaku Ryoho. 1997 Aug;24(10):1213-20. Review. Japanese. PubMed PMID: 9279339. 7: Cachat F, Guignard JP. [The kidney in children under chemotherapy]. Rev Med Suisse Romande. 1996 Dec;116(12):985-93. Review. French. PubMed PMID: 9026889. 8: [Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994]. Ann Gastroenterol Hepatol (Paris). 1995 Sep;31(4):226-30, 233-6. Review. French. PubMed PMID: 7486820. 9: Shparik IaV. [Adjuvant chemotherapy of gastric cancer]. Klin Khir. 1995;(5):38-41. Review. Ukrainian. PubMed PMID: 8646632. 10: Mezger J. [Adjuvant therapy in colorectal carcinomas]. Dtsch Med Wochenschr. 1994 Dec 2;119(48):1663-8. Review. German. PubMed PMID: 7988367.